ADREVIEW

This brand name is authorized in United States. It is also authorized in Estonia, France, Spain, UK.

Active ingredients

The drug ADREVIEW contains one active pharmaceutical ingredient (API):

1	Iobenguane ¹²³I UNII P2TH1XYZ84 - IOBENGUANE I-123
	Iobenguane is similar in structure to the antihypertensive drug guanethedine and to the neurotransmitter norepinephrine (NE). Iobenguane is, therefore, largely subject to the same uptake and accumulation pathways as NE. Iobenguane accumulates in adrenergically innervated tissues such as the adrenal medulla, salivary glands, heart, liver, spleen and lungs as well as tumors derived from the neural crest. By labeling iobenguane with the isotope iodine 123, it is possible to obtain scintigraphic images of the organs and tissues in which the radiopharmaceutical accumulates.
	Read more about Iobenguane ¹²³I

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ADREVIEW Solution for injection	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
V09IX01	Iobenguane (123I)	V Various → V09 Diagnostic radiopharmaceuticals → V09I Tumour detection → V09IX Other diagnostic radiopharmaceuticals for tumour detection
Discover more medicines within V09IX01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1236596, 1308653, 1708769, 1752016
ES	Centro de información online de medicamentos de la AEMPS	68722
FR	Base de données publique des médicaments	65884582
GB	Medicines & Healthcare Products Regulatory Agency	398499, 398503, 398506, 398510, 398514, 398517, 398526, 398529
US	FDA, National Drug Code	17156-235